Top
Introduction
Preclinical
Results
Exclusions
Randomized Controlled Trials
Heterogeneity
Discussion
Conclusion
Study Notes
Methods and Data
Supplementary
References

All studies
Mortality
Hospitalization
Recovery
Viral clearance
Exclusions
All RCTs

Feedback
Home
Show Outline
Top   Intro   Preclinical   Results   Exc.   RCT   Heterogeneity   Discussion   Conclusion   StudyNotes   Appendix   SupplementarySupp.   ReferencesRef.
Home   COVID-19 treatment studies for Lactoferrin  COVID-19 treatment studies for Lactoferrin  C19 studies: Lactoferrin  Lactoferrin   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
Loading...
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc
Lactoferrin for COVID-19: real-time meta analysis of 4 studies
Covid Analysis, September 25, 2022, DRAFT
https://c19early.com/lfmeta.html
 
0 0.5 1 1.5+ All studies 48% 4 786 Improvement, Studies, Patients Relative Risk Mortality 79% 1 547 Hospitalization 76% 1 121 Recovery -20% 2 175 Viral clearance 45% 2 185 RCTs 25% 1 54 Early 76% 1 121 Late 48% 3 665 Lactoferrin for COVID-19 c19early.com/lf Sep 2022 Favorslactoferrin Favorscontrol after exclusions
Statistically significant improvement is seen for viral clearance. 2 studies from 2 independent teams (both from the same country) show statistically significant improvements in isolation (1 for the most serious outcome).
Meta analysis using the most serious outcome reported shows 48% [30‑62%] improvement. Results are worse for Randomized Controlled Trials and similar after exclusions. Early treatment is more effective than late treatment.
0 0.5 1 1.5+ All studies 48% 4 786 Improvement, Studies, Patients Relative Risk Mortality 79% 1 547 Hospitalization 76% 1 121 Recovery -20% 2 175 Viral clearance 45% 2 185 RCTs 25% 1 54 Early 76% 1 121 Late 48% 3 665 Lactoferrin for COVID-19 c19early.com/lf Sep 2022 Favorslactoferrin Favorscontrol after exclusions
Currently there is limited data, with only 786 patients in trials to date.
No treatment, vaccine, or intervention is 100% effective and available. All practical, effective, and safe means should be used based on risk/benefit analysis. Multiple treatments are typically used in combination, and other treatments may be more effective. Only 25% of lactoferrin studies show zero events with treatment. The quality of non-prescription supplements can vary widely [Crawford, Crighton].
All data to reproduce this paper and sources are in the appendix.
Highlights
Lactoferrin reduces risk for COVID-19 with very high confidence for pooled analysis and low confidence for mortality and viral clearance, however increased risk is seen with very low confidence for recovery.
We show traditional outcome specific analyses and combined evidence from all studies, incorporating treatment delay, a primary confounding factor in COVID-19 studies.
Real-time updates and corrections, transparent analysis with all results in the same format, consistent protocol for 47 treatments.
A
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Rosa 76% 0.24 [0.01-5.85] hosp. 0/82 1/39 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.39 Early treatment 76% 0.24 [0.01-5.85] 0/82 1/39 76% improvement Algahtani (RCT) 25% 0.75 [0.14-4.09] no recov. 3/36 2/18 Improvement, RR [CI] Treatment Control Campione 47% 0.53 [0.38-0.72] viral time 32 (n) 32 (n) Shousha 79% 0.21 [0.03-1.48] death 1/46 52/501 Tau​2 = 0.00, I​2 = 0.0%, p < 0.0001 Late treatment 48% 0.52 [0.38-0.71] 4/114 54/551 48% improvement All studies 48% 0.52 [0.38-0.70] 4/196 55/590 48% improvement 4 lactoferrin COVID-19 studies c19early.com/lf Sep 2022 Tau​2 = 0.00, I​2 = 0.0%, p < 0.0001 Effect extraction pre-specified(most serious outcome, see appendix) Favors lactoferrin Favors control
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Rosa 76% hospitalization Improvement Relative Risk [CI] Tau​2 = 0.00, I​2 = 0.0%, p = 0.39 Early treatment 76% 76% improvement Algahtani (RCT) 25% recovery Campione 47% viral- Shousha 79% death Tau​2 = 0.00, I​2 = 0.0%, p < 0.0001 Late treatment 48% 48% improvement All studies 48% 48% improvement 4 lactoferrin COVID-19 studies c19early.com/lf Sep 2022 Tau​2 = 0.00, I​2 = 0.0%, p < 0.0001 Effect extraction pre-specifiedRotate device for details Favors lactoferrin Favors control
Figure 1. A. Random effects meta-analysis. This plot shows pooled effects, discussion can be found in the heterogeneity section, and results for specific outcomes can be found in the individual outcome analyses. Effect extraction is pre-specified, using the most serious outcome reported. For details of effect extraction see the appendix. B. Scatter plot showing the distribution of effects reported in studies. C. History of all reported effects (chronological within treatment stages).
Introduction
We analyze all significant studies concerning the use of lactoferrin for COVID-19. Search methods, inclusion criteria, effect extraction criteria (more serious outcomes have priority), all individual study data, PRISMA answers, and statistical methods are detailed in Appendix 1. We present random effects meta-analysis results for all studies, for studies within each treatment stage, for individual outcomes, for peer-reviewed studies, for Randomized Controlled Trials (RCTs), and after exclusions.
Figure 2 shows stages of possible treatment for COVID-19. Prophylaxis refers to regularly taking medication before becoming sick, in order to prevent or minimize infection. Early Treatment refers to treatment immediately or soon after symptoms appear, while Late Treatment refers to more delayed treatment.
Figure 2. Treatment stages.
Preclinical Research
2 In Silico studies support the efficacy of lactoferrin [Cutone, Miotto].
5 In Vitro studies support the efficacy of lactoferrin [Cutone, Mirabelli, Ostrov, Piacentini, Salaris].
Preclinical research is an important part of the development of treatments, however results may be very different in clinical trials. Preclinical results are not used in this paper.
Results
Figure 3 shows a visual overview of the results, with details in Table 1 and Table 2. Figure 4, 5, 6, 7, and 8 show forest plots for a random effects meta-analysis of all studies with pooled effects, mortality results, hospitalization, recovery, and viral clearance.
0 0.5 1 1.5+ ALL STUDIES MORTALITY HOSPITALIZATION RECOVERY VIRAL CLEARANCE RCTS After Exclusions ALL STUDIES All Early Late Lactoferrin for COVID-19 C19EARLY.COM/LF SEP 2022
Figure 3. Overview of results.
Treatment timeNumber of studies reporting positive effects Total number of studiesPercentage of studies reporting positive effects Random effects meta-analysis results
Early treatment 1 1 100% 76% improvement
RR 0.24 [0.01‑5.85]
p = 0.39
Late treatment 3 3 100% 48% improvement
RR 0.52 [0.38‑0.71]
p < 0.0001
All studies 4 4 100% 48% improvement
RR 0.52 [0.38‑0.70]
p < 0.0001
Table 1. Results by treatment stage.
Studies Early treatment Late treatment PatientsAuthors
All studies 476% [-485‑99%]48% [29‑62%] 786 64
With exclusions 376% [-485‑99%]47% [27‑61%] 239 46
Randomized Controlled TrialsRCTs 125% [-309‑86%] 54 6
Table 2. Results by treatment stage for all studies and with different exclusions.
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Rosa 76% 0.24 [0.01-5.85] hosp. 0/82 1/39 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.39 Early treatment 76% 0.24 [0.01-5.85] 0/82 1/39 76% improvement Algahtani (RCT) 25% 0.75 [0.14-4.09] no recov. 3/36 2/18 Improvement, RR [CI] Treatment Control Campione 47% 0.53 [0.38-0.72] viral time 32 (n) 32 (n) Shousha 79% 0.21 [0.03-1.48] death 1/46 52/501 Tau​2 = 0.00, I​2 = 0.0%, p < 0.0001 Late treatment 48% 0.52 [0.38-0.71] 4/114 54/551 48% improvement All studies 48% 0.52 [0.38-0.70] 4/196 55/590 48% improvement 4 lactoferrin COVID-19 studies c19early.com/lf Sep 2022 Tau​2 = 0.00, I​2 = 0.0%, p < 0.0001 Effect extraction pre-specified(most serious outcome, see appendix) Favors lactoferrin Favors control
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Rosa 76% hospitalization Improvement Relative Risk [CI] Tau​2 = 0.00, I​2 = 0.0%, p = 0.39 Early treatment 76% 76% improvement Algahtani (RCT) 25% recovery Campione 47% viral- Shousha 79% death Tau​2 = 0.00, I​2 = 0.0%, p < 0.0001 Late treatment 48% 48% improvement All studies 48% 48% improvement 4 lactoferrin COVID-19 studies c19early.com/lf Sep 2022 Tau​2 = 0.00, I​2 = 0.0%, p < 0.0001 Effect extraction pre-specifiedRotate device for details Favors lactoferrin Favors control
Figure 4. Random effects meta-analysis for all studies with pooled effects. This plot shows pooled effects, discussion can be found in the heterogeneity section, and results for specific outcomes can be found in the individual outcome analyses. Effect extraction is pre-specified, using the most serious outcome reported. For details of effect extraction see the appendix.
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Shousha 79% 0.21 [0.03-1.48] 1/46 52/501 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.12 Late treatment 79% 0.21 [0.03-1.48] 1/46 52/501 79% improvement All studies 79% 0.21 [0.03-1.48] 1/46 52/501 79% improvement 1 lactoferrin COVID-19 mortality result c19early.com/lf Sep 2022 Tau​2 = 0.00, I​2 = 0.0%, p = 0.12 Favors lactoferrin Favors control
Figure 5. Random effects meta-analysis for mortality results.
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Rosa 76% 0.24 [0.01-5.85] hosp. 0/82 1/39 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.39 Early treatment 76% 0.24 [0.01-5.85] 0/82 1/39 76% improvement All studies 76% 0.24 [0.01-5.85] 0/82 1/39 76% improvement 1 lactoferrin COVID-19 hospitalization result c19early.com/lf Sep 2022 Tau​2 = 0.00, I​2 = 0.0%, p = 0.39 Favors lactoferrin Favors control
Figure 6. Random effects meta-analysis for hospitalization.
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Rosa -40% 1.40 [0.54-3.64] recov. time 82 (n) 39 (n) Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.5 Early treatment -40% 1.40 [0.54-3.64] 0/82 0/39 -40% improvement Algahtani (RCT) 25% 0.75 [0.14-4.09] no recov. 3/36 2/18 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.75 Late treatment 25% 0.75 [0.14-4.09] 3/36 2/18 25% improvement All studies -20% 1.20 [0.52-2.77] 3/118 2/57 -20% improvement 2 lactoferrin COVID-19 recovery results c19early.com/lf Sep 2022 Tau​2 = 0.00, I​2 = 0.0%, p = 0.67 Favors lactoferrin Favors control
Figure 7. Random effects meta-analysis for recovery.
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Rosa 39% 0.61 [0.40-0.92] viral time 82 (n) 39 (n) Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.02 Early treatment 39% 0.61 [0.40-0.92] 0/82 0/39 39% improvement Campione 47% 0.53 [0.38-0.72] viral time 32 (n) 32 (n) Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.0001 Late treatment 47% 0.53 [0.38-0.72] 0/32 0/32 47% improvement All studies 45% 0.55 [0.43-0.72] 0/114 0/71 45% improvement 2 lactoferrin COVID-19 viral clearance results c19early.com/lf Sep 2022 Tau​2 = 0.00, I​2 = 0.0%, p < 0.0001 Favors lactoferrin Favors control
Figure 8. Random effects meta-analysis for viral clearance.
Exclusions
To avoid bias in the selection of studies, we analyze all non-retracted studies. Here we show the results after excluding studies with major issues likely to alter results, non-standard studies, and studies where very minimal detail is currently available. Our bias evaluation is based on analysis of each study and identifying when there is a significant chance that limitations will substantially change the outcome of the study. We believe this can be more valuable than checklist-based approaches such as Cochrane GRADE, which may underemphasize serious issues not captured in the checklists, overemphasize issues unlikely to alter outcomes in specific cases (for example, lack of blinding for an objective mortality outcome, or certain specifics of randomization with a very large effect size), or be easily influenced by potential bias. However, they can also be very high quality.
The studies excluded are as below. Figure 9 shows a forest plot for random effects meta-analysis of all studies after exclusions.
[Rosa], excessive unadjusted differences between groups. Excluded results: no recovery.
[Shousha], confounding by indication, unadjusted results and treatment used selectively per official protocol, unadjusted results with no group details.
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Rosa 76% 0.24 [0.01-5.85] hosp. 0/82 1/39 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.39 Early treatment 76% 0.24 [0.01-5.85] 0/82 1/39 76% improvement Algahtani (RCT) 25% 0.75 [0.14-4.09] no recov. 3/36 2/18 Improvement, RR [CI] Treatment Control Campione 47% 0.53 [0.38-0.72] viral time 32 (n) 32 (n) Tau​2 = 0.00, I​2 = 0.0%, p = 0.0001 Late treatment 47% 0.53 [0.39-0.73] 3/68 2/50 47% improvement All studies 47% 0.53 [0.39-0.72] 3/150 3/89 47% improvement 3 lactoferrin COVID-19 studies after exclusions c19early.com/lf Sep 2022 Tau​2 = 0.00, I​2 = 0.0%, p < 0.0001 Effect extraction pre-specified(most serious outcome, see appendix) Favors lactoferrin Favors control
Figure 9. Random effects meta-analysis for all studies after exclusions. This plot shows pooled effects, discussion can be found in the heterogeneity section, and results for specific outcomes can be found in the individual outcome analyses. Effect extraction is pre-specified, using the most serious outcome reported. For details of effect extraction see the appendix.
Randomized Controlled Trials (RCTs)
Figure 10 shows a forest plot for random effects meta-analysis of all Randomized Controlled Trials. Table 3 summarizes the results. Currently there is only one RCT.
RCTs help to make study groups more similar, however they are subject to many biases, including age bias, treatment delay bias, severity of illness bias, regulation bias, recruitment bias, trial design bias, followup time bias, selective reporting bias, fraud bias, hidden agenda bias, vested interest bias, publication bias, and publication delay bias [Jadad], all of which have been observed with COVID-19 RCTs.
RCTs have a bias against finding an effect for interventions that are widely available — patients that believe they need the intervention are more likely to decline participation and take the intervention. This is illustrated with the extreme example of an RCT showing no significant differences for use of a parachute when jumping from a plane [Yeh]. RCTs for lactoferrin are more likely to enroll low-risk participants that do not need treatment to recover, making the results less applicable to clinical practice. This bias is likely to be greater for widely known treatments. Note that this bias does not apply to the typical pharmaceutical trial of a new drug that is otherwise unavailable.
Evidence shows that non-RCT trials can also provide reliable results. [Concato] find that well-designed observational studies do not systematically overestimate the magnitude of the effects of treatment compared to RCTs. [Anglemyer] summarized reviews comparing RCTs to observational studies and found little evidence for significant differences in effect estimates. [Lee] shows that only 14% of the guidelines of the Infectious Diseases Society of America were based on RCTs. Evaluation of studies relies on an understanding of the study and potential biases. Limitations in an RCT can outweigh the benefits, for example excessive dosages, excessive treatment delays, or Internet survey bias could have a greater effect on results. Ethical issues may also prevent running RCTs for known effective treatments. For more on issues with RCTs see [Deaton, Nichol].
In summary, we need to evaluate each trial on its own merits. RCTs for a given medication and disease may be more reliable, however they may also be less reliable. For example, consider trials for an off-patent medication, very high conflict of interest trials may be more likely to be RCTs (and more likely to be large trials that dominate meta analyses).
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Algahtani (RCT) 25% 0.75 [0.14-4.09] no recov. 3/36 2/18 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.75 Late treatment 25% 0.75 [0.14-4.09] 3/36 2/18 25% improvement All studies 25% 0.75 [0.14-4.09] 3/36 2/18 25% improvement 1 lactoferrin COVID-19 Randomized Controlled Trials c19early.com/lf Sep 2022 Tau​2 = 0.00, I​2 = 0.0%, p = 0.75 Effect extraction pre-specified(most serious outcome, see appendix) Favors lactoferrin Favors control
Figure 10. Random effects meta-analysis for all Randomized Controlled Trials. This plot shows pooled effects, discussion can be found in the heterogeneity section, and results for specific outcomes can be found in the individual outcome analyses. Effect extraction is pre-specified, using the most serious outcome reported. For details of effect extraction see the appendix.
Treatment timeNumber of studies reporting positive effects Total number of studiesPercentage of studies reporting positive effects Random effects meta-analysis results
Randomized Controlled Trials 1 1 100% 25% improvement
RR 0.75 [0.14‑4.09]
p = 0.75
Table 3. Randomized Controlled Trial results.
Heterogeneity
Heterogeneity in COVID-19 studies arises from many factors including:
Treatment delay.
The time between infection or the onset of symptoms and treatment may critically affect how well a treatment works. For example an antiviral may be very effective when used early but may not be effective in late stage disease, and may even be harmful. Oseltamivir, for example, is generally only considered effective for influenza when used within 0-36 or 0-48 hours [McLean, Treanor]. Figure 11 shows a mixed-effects meta-regression for efficacy as a function of treatment delay in COVID-19 studies from 47 treatments, showing that efficacy declines rapidly with treatment delay. Early treatment is critical for COVID-19.
Figure 11. Meta-regression showing efficacy as a function of treatment delay in COVID-19 studies from 47 treatments. Early treatment is critical.
Patient demographics.
Details of the patient population including age and comorbidities may critically affect how well a treatment works. For example, many COVID-19 studies with relatively young low-comorbidity patients show all patients recovering quickly with or without treatment. In such cases, there is little room for an effective treatment to improve results (as in [López-Medina]).
Effect measured.
Efficacy may differ significantly depending on the effect measured, for example a treatment may be very effective at reducing mortality, but less effective at minimizing cases or hospitalization. Or a treatment may have no effect on viral clearance while still being effective at reducing mortality.
Variants.
There are many different variants of SARS-CoV-2 and efficacy may depend critically on the distribution of variants encountered by the patients in a study. For example, the Gamma variant shows significantly different characteristics [Faria, Karita, Nonaka, Zavascki]. Different mechanisms of action may be more or less effective depending on variants, for example the viral entry process for the omicron variant has moved towards TMPRSS2-independent fusion, suggesting that TMPRSS2 inhibitors may be less effective [Peacock, Willett].
Regimen.
Effectiveness may depend strongly on the dosage and treatment regimen.
Other treatments.
The use of other treatments may significantly affect outcomes, including anything from supplements, other medications, or other kinds of treatment such as prone positioning.
Medication quality.
The quality of medications may vary significantly between manufacturers and production batches, which may significantly affect efficacy and safety. [Williams] analyze ivermectin from 11 different sources, showing highly variable antiparasitic efficacy across different manufacturers. [Xu] analyze a treatment from two different manufacturers, showing 9 different impurities, with significantly different concentrations for each manufacturer. Non-prescription supplements may show very wide variations in quality [Crawford, Crighton].
Meta analysis.
The distribution of studies will alter the outcome of a meta analysis. Consider a simplified example where everything is equal except for the treatment delay, and effectiveness decreases to zero or below with increasing delay. If there are many studies using very late treatment, the outcome may be negative, even though the treatment may be very effective when used earlier.
In general, by combining heterogeneous studies, as all meta analyses do, we run the risk of obscuring an effect by including studies where the treatment is less effective, not effective, or harmful.
When including studies where a treatment is less effective we expect the estimated effect size to be lower than that for the optimal case. We do not a priori expect that pooling all studies will create a positive result for an effective treatment. Looking at all studies is valuable for providing an overview of all research, important to avoid cherry-picking, and informative when a positive result is found despite combining less-optimal situations. However, the resulting estimate does not apply to specific cases such as early treatment in high-risk populations. While we present pooled results for all studies, we also present individual outcome and treatment time analyses, which are more relevant for specific use cases.
Discussion
Publication bias.
Publishing is often biased towards positive results, however evidence suggests that there may be a negative bias for inexpensive treatments for COVID-19. Both negative and positive results are very important for COVID-19, media in many countries prioritizes negative results for inexpensive treatments (inverting the typical incentive for scientists that value media recognition), and there are many reports of difficulty publishing positive results [Boulware, Meeus, Meneguesso]. For lactoferrin, there is currently not enough data to evaluate publication bias with high confidence.
One method to evaluate bias is to compare prospective vs. retrospective studies. Prospective studies are more likely to be published regardless of the result, while retrospective studies are more likely to exhibit bias. For example, researchers may perform preliminary analysis with minimal effort and the results may influence their decision to continue. Retrospective studies also provide more opportunities for the specifics of data extraction and adjustments to influence results.
The median effect size for retrospective studies is 77% improvement, compared to 36% for prospective studies, suggesting a potential bias towards publishing results showing higher efficacy. Figure 12 shows a scatter plot of results for prospective and retrospective studies.
Figure 12. Prospective vs. retrospective studies.
Funnel plot analysis.
Funnel plots have traditionally been used for analyzing publication bias. This is invalid for COVID-19 acute treatment trials — the underlying assumptions are invalid, which we can demonstrate with a simple example. Consider a set of hypothetical perfect trials with no bias. Figure 13 plot A shows a funnel plot for a simulation of 80 perfect trials, with random group sizes, and each patient's outcome randomly sampled (10% control event probability, and a 30% effect size for treatment). Analysis shows no asymmetry (p > 0.05). In plot B, we add a single typical variation in COVID-19 treatment trials — treatment delay. Consider that efficacy varies from 90% for treatment within 24 hours, reducing to 10% when treatment is delayed 3 days. In plot B, each trial's treatment delay is randomly selected. Analysis now shows highly significant asymmetry, p < 0.0001, with six variants of Egger's test all showing p < 0.05 [Egger, Harbord, Macaskill, Moreno, Peters, Rothstein, Rücker, Stanley]. Note that these tests fail even though treatment delay is uniformly distributed. In reality treatment delay is more complex — each trial has a different distribution of delays across patients, and the distribution across trials may be biased (e.g., late treatment trials may be more common). Similarly, many other variations in trials may produce asymmetry, including dose, administration, duration of treatment, differences in SOC, comorbidities, age, variants, and bias in design, implementation, analysis, and reporting.
Figure 13. Example funnel plot analysis for simulated perfect trials.
Conflicts of interest.
Pharmaceutical drug trials often have conflicts of interest whereby sponsors or trial staff have a financial interest in the outcome being positive. Lactoferrin for COVID-19 lacks this because it is an inexpensive and widely available supplement. In contrast, most COVID-19 lactoferrin trials have been run by physicians on the front lines with the primary goal of finding the best methods to save human lives and minimize the collateral damage caused by COVID-19. While pharmaceutical companies are careful to run trials under optimal conditions (for example, restricting patients to those most likely to benefit, only including patients that can be treated soon after onset when necessary, and ensuring accurate dosing), not all lactoferrin trials represent the optimal conditions for efficacy.
Early/late vs. mild/moderate/severe.
Some analyses classify treatment based on early/late administration (as we do here), while others distinguish between mild/moderate/severe cases. We note that viral load does not indicate degree of symptoms — for example patients may have a high viral load while being asymptomatic. With regard to treatments that have antiviral properties, timing of treatment is critical — late administration may be less helpful regardless of severity.
Conclusion
Lactoferrin is an effective treatment for COVID-19. Statistically significant improvement is seen for viral clearance. 2 studies from 2 independent teams (both from the same country) show statistically significant improvements in isolation (1 for the most serious outcome). Meta analysis using the most serious outcome reported shows 48% [30‑62%] improvement. Results are worse for Randomized Controlled Trials and similar after exclusions. Early treatment is more effective than late treatment.
Currently there is limited data, with only 786 patients in trials to date.
Study Notes
0 0.5 1 1.5 2+ Unresolved fever 25% Improvement Relative Risk Unresolved fatigue 33% Unresolved cough 0% Unresolved headache 0% Unresolved loss of smell.. 25% c19early.com/lf Algahtani et al. Lactoferrin for COVID-19 RCT LATE Favors lactoferrin Favors control
[Algahtani] RCT 54 hospitalized patients in Egypt, showing no significant differences in recovery with lactoferrin treatment. 200mg lactoferrin orally once daily (group 1) or 200mg lactoferrin orally twice daily (group 2).
0 0.5 1 1.5 2+ Time to viral- 47% Improvement Relative Risk Time to viral- (b) 56% c19early.com/lf Campione et al. Lactoferrin for COVID-19 LATE Favors lactoferrin Favors control
[Campione] Small prospective study in Italy with 32 lactoferrin patients, 32 SOC, and 28 patients with no treatment, showing significantly faster viral clearance and improved recovery with treatment. Oral and intranasal lactoferrin.
0 0.5 1 1.5 2+ Hospitalization 76% Improvement Relative Risk Recovery time -40% Time to viral- 39% primary c19early.com/lf Rosa et al. Lactoferrin for COVID-19 EARLY TREATMENT Favors lactoferrin Favors control
[Rosa] Retrospective survey based study in Italy with 82 patients treated with lactoferrin, and 39 control patients, showing significantly faster viral clearance with treatment. There was no significant difference in recovery time overall, however the treatment group had significantly more moderate condition patients (39% versus 8%), and improved recovery was seen with treatment as age increased. Median dose for asymptomatic patients was 400mg/day, for paucisymptomatic patients 600mg/day, and for moderate condition patients 1000mg three times a day.
0 0.5 1 1.5 2+ Mortality 79% unadjusted Improvement Relative Risk c19early.com/lf Shousha et al. Lactoferrin for COVID-19 LATE Favors lactoferrin Favors control
[Shousha] Retrospective 547 hospitalized COVID+ patients in Egypt, showing lower mortality with lactoferrin treatment (without statistical significance).
We performed ongoing searches of PubMed, medRxiv, ClinicalTrials.gov, The Cochrane Library, Google Scholar, Collabovid, Research Square, ScienceDirect, Oxford University Press, the reference lists of other studies and meta-analyses, and submissions to the site c19early.com. Search terms were lactoferrin, filtered for papers containing the terms COVID-19 or SARS-CoV-2. Automated searches are performed every few hours with notification of new matches. All studies regarding the use of lactoferrin for COVID-19 that report a comparison with a control group are included in the main analysis. Sensitivity analysis is performed, excluding studies with major issues, epidemiological studies, and studies with minimal available information. This is a living analysis and is updated regularly.
We extracted effect sizes and associated data from all studies. If studies report multiple kinds of effects then the most serious outcome is used in pooled analysis, while other outcomes are included in the outcome specific analyses. For example, if effects for mortality and cases are both reported, the effect for mortality is used, this may be different to the effect that a study focused on. If symptomatic results are reported at multiple times, we used the latest time, for example if mortality results are provided at 14 days and 28 days, the results at 28 days are used. Mortality alone is preferred over combined outcomes. Outcomes with zero events in both arms were not used (the next most serious outcome is used — no studies were excluded). For example, in low-risk populations with no mortality, a reduction in mortality with treatment is not possible, however a reduction in hospitalization, for example, is still valuable. Clinical outcome is considered more important than PCR testing status. When basically all patients recover in both treatment and control groups, preference for viral clearance and recovery is given to results mid-recovery where available (after most or all patients have recovered there is no room for an effective treatment to do better). If only individual symptom data is available, the most serious symptom has priority, for example difficulty breathing or low SpO2 is more important than cough. When results provide an odds ratio, we computed the relative risk when possible, or converted to a relative risk according to [Zhang]. Reported confidence intervals and p-values were used when available, using adjusted values when provided. If multiple types of adjustments are reported including propensity score matching (PSM), the PSM results are used. Adjusted primary outcome results have preference over unadjusted results for a more serious outcome when the adjustments significantly alter results. When needed, conversion between reported p-values and confidence intervals followed [Altman, Altman (B)], and Fisher's exact test was used to calculate p-values for event data. If continuity correction for zero values is required, we use the reciprocal of the opposite arm with the sum of the correction factors equal to 1 [Sweeting]. Results are expressed with RR < 1.0 favoring treatment, and using the risk of a negative outcome when applicable (for example, the risk of death rather than the risk of survival). If studies only report relative continuous values such as relative times, the ratio of the time for the treatment group versus the time for the control group is used. Calculations are done in Python (3.10.6) with scipy (1.9.1), pythonmeta (1.26), numpy (1.23.2), statsmodels (0.13.2), and plotly (5.10.0).
Forest plots are computed using PythonMeta [Deng] with the DerSimonian and Laird random effects model (the fixed effect assumption is not plausible in this case) and inverse variance weighting. Mixed-effects meta-regression results are computed with R (4.1.2) using the metafor (3.0-2) and rms (6.2-0) packages, and using the most serious sufficiently powered outcome.
We received no funding, this research is done in our spare time. We have no affiliations with any pharmaceutical companies or political parties.
We have classified studies as early treatment if most patients are not already at a severe stage at the time of treatment (for example based on oxygen status or lung involvement), and treatment started within 5 days of the onset of symptoms. If studies contain a mix of early treatment and late treatment patients, we consider the treatment time of patients contributing most to the events (for example, consider a study where most patients are treated early but late treatment patients are included, and all mortality events were observed with late treatment patients). We note that a shorter time may be preferable. Antivirals are typically only considered effective when used within a shorter timeframe, for example 0-36 or 0-48 hours for oseltamivir, with longer delays not being effective [McLean, Treanor].
A summary of study results is below. Please submit updates and corrections at the bottom of this page.
A summary of study results is below. Please submit updates and corrections at https://c19early.com/lfmeta.html.
Effect extraction follows pre-specified rules as detailed above and gives priority to more serious outcomes. For pooled analyses, the first (most serious) outcome is used, which may differ from the effect a paper focuses on. Other outcomes are used in outcome specific analyses.
[Rosa], 9/21/2021, retrospective, Italy, peer-reviewed, 8 authors, study period October 2020 - March 2021. risk of hospitalization, 75.6% lower, RR 0.24, p = 0.32, treatment 0 of 82 (0.0%), control 1 of 39 (2.6%), NNT 39, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
recovery time, 40.0% higher, relative time 1.40, p = 0.50, treatment 82, control 39, excluded in exclusion analyses: excessive unadjusted differences between groups.
time to viral-, 39.4% lower, relative time 0.61, p = 0.02, treatment 82, control 39, inverted to make RR<1 favor treatment, Cox regression, primary outcome.
Effect extraction follows pre-specified rules as detailed above and gives priority to more serious outcomes. For pooled analyses, the first (most serious) outcome is used, which may differ from the effect a paper focuses on. Other outcomes are used in outcome specific analyses.
[Algahtani], 8/19/2021, Randomized Controlled Trial, Egypt, peer-reviewed, 6 authors, study period 8 July, 2020 - 18 September, 2020. risk of unresolved fever, 25.0% lower, RR 0.75, p = 1.00, treatment 3 of 36 (8.3%), control 2 of 18 (11.1%), NNT 36, day 7.
risk of unresolved fatigue, 33.3% lower, RR 0.67, p = 0.67, treatment 4 of 36 (11.1%), control 3 of 18 (16.7%), NNT 18, day 7.
risk of unresolved cough, no change, RR 1.00, p = 1.00, treatment 8 of 36 (22.2%), control 4 of 18 (22.2%), day 7.
risk of unresolved headache, no change, RR 1.00, p = 1.00, treatment 4 of 36 (11.1%), control 2 of 18 (11.1%), day 7.
risk of unresolved loss of smell/taste, 25.0% lower, RR 0.75, p = 0.72, treatment 6 of 36 (16.7%), control 4 of 18 (22.2%), NNT 18, day 7.
[Campione], 10/19/2021, prospective, Italy, peer-reviewed, 32 authors. time to viral-, 47.5% lower, relative time 0.53, p < 0.001, treatment 32, control 32, vs. SOC.
time to viral-, 56.3% lower, relative time 0.44, p < 0.001, treatment 32, control 28, vs. untreated.
[Shousha], 10/28/2021, retrospective, Egypt, peer-reviewed, 18 authors, study period 15 April, 2020 - 29 July, 2020, excluded in exclusion analyses: confounding by indication, unadjusted results and treatment used selectively per official protocol, unadjusted results with no group details. risk of death, 79.1% lower, RR 0.21, p = 0.11, treatment 1 of 46 (2.2%), control 52 of 501 (10.4%), NNT 12, unadjusted.
Supplementary Data
References
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit